USD $3660.00
IndiaKeytruda (Pembrolizumab) is an immunotherapy medication used to treat various types of cancer by enhancing the body's immune response against cancer cells. It is a monoclonal antibody that inhibits the programmed cell death protein 1 (PD-1) pathway, allowing T-cells to detect and attack cancer more effectively.
The dosage of Keytruda is determined by a healthcare professional based on the patient's specific condition and response to treatment. It is typically administered every 3 weeks. Patients should follow the prescribed treatment plan and attend all scheduled appointments.
Common side effects of Keytruda may include:
Serious side effects can occur and should be reported to a healthcare provider immediately, including symptoms of an allergic reaction, lung problems, liver problems, and severe skin reactions.
Keytruda is used to treat various cancers, including melanoma, non-small cell lung cancer, and other malignancies that express PD-L1.
Keytruda is administered via intravenous infusion by a healthcare professional.
If you miss a dose, contact your healthcare provider for instructions on when to reschedule your treatment.
Yes, Keytruda may be used in combination with other therapies depending on the specific cancer type and treatment plan.
